About

WHO WE ARE

Treovir LLC

Treovir was founded in 2019 to develop and commercialize G207 for recurrent glioblastoma in children.

G207 is a targeted oncolytic immunotherapy that has demonstrated improved survival in a phase 1 clinical study in 12 pediatric patients.

In 2021, Treovir will launch a Phase 2 study designed to support registration of G207 for treatment of pediatric glioma.   If successful, G207 would be the first-ever approved therapy for pediatric glioma.

G207 has been been designated for Fast Track status by the FDA.
G207 has been granted orphan product designation for treatment of glioma, medulloblatoma and pediatric neuroectodermal tumors (PNET)
>
0
Children diagnosed every year in the US with brain tumors
0
FDA-Approved therapies to treat pediatric brain tumors
0
Adult and pediatric brain tumor clinical studies to date with G207
>
0
months
Overall Survival using G207 in Phase 1 pediatric study with no serious side effects

Treovir is committed to ensuring access and affordability for all patients .